Histopathologic subtype-specific genomic profiles of renal cell carcinomas identified by high-resolution whole-genome single nucleotide polymorphism array analysis
- Authors:
- Akira Yokomizo
- Ken Yamamoto
- Kenji Furuno
- Masaki Shiota
- Katsunori Tatsugami
- Kentaro Kuroiwa
- Seiji Naito
View Affiliations
Affiliations: Department of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan, Division of Molecular Population Genetics, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan
- Published online on: September 23, 2010 https://doi.org/10.3892/ol.2010.187
-
Pages:
1073-1078
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
To elucidate the novel and common genetic changes in histopathologic subtype-specific profiles of renal cell carcinomas (RCCs), a newly developed high-resolution whole-genome array analysis was applied. Human CNV370-Duo DNA Analysis BeadChip (genotype 370K) was used in a panel of 22 primary clear cell RCCs (ccRCCs), seven papillary RCCs (PRCCs) (six type II and one type I) and eight chromophobe RCCs (ChRCCs). In ccRCC, a chromosome 3p loss was identified in 95% of the carcinomas, suggesting that 3p loss is the first stage in ccRCC carcinogenesis. Other frequent changes included losses of 1p (23%), 3q (46%) and 8p (32%), and gains of 5q (32%), 7p (27%), 7q (27%) and 1q (23%). The most frequent chromosomal losses in PRCC (43%) were noted in 3p and 3q, followed by 29% of losses of 1p, 1q, 11q, 18q, 22p and 22q, and gains of 20q (57%), 20p (43%), 8q (43%) and 12q (43%). Loss of the entire chromosomes 1, 2, 6, 8, 10, 13 or 17 was noted in patients with ChRCC. A high-density single nucleotide polymorphism array analysis confirmed that partial chromosomal changes rarely occur in ChRCC. Additionally, 32 microdeletions and 10 microamplifications of less than 1 Mb were detected, which may represent potential candidate tumor suppressor genes and oncogenes, respectively.
View References
|
1
|
Thoenes W, Storkel S and Rumpelt HJ:
Histopathology and classification of renal cell tumors (adenomas,
oncocytomas and carcinomas). The basic cytological and
histopathological elements and their use for diagnostics. Pathol
Res Pract. 181:125–143. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Monzon FA, Hagenkord JM, Lyons-Weiler MA,
et al: Whole genome SNP arrays as a potential diagnostic tool for
the detection of characteristic chromosomal aberrations in renal
epithelial tumors. Mod Pathol. 21:599–608. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herrmann E, Brinkmann OA, Bode ME, et al:
Histologic subtype of metastatic renal cell carcinoma predicts
response to combined immunochemotherapy with interleukin 2,
interferon alpha and 5-fluorouracil. Eur Urol. 51:1625–1631. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clifford SC, Prowse AH, Affara NA, Buys CH
and Maher ER: Inactivation of the von Hippel-Lindau (VHL) tumour
suppressor gene and allelic losses at chromosome arm 3p in primary
renal cell carcinoma: evidence for a VHL-independent pathway in
clear cell renal tumourigenesis. Genes Chromosomes Cancer.
22:200–209. 1998. View Article : Google Scholar
|
|
5
|
Eto M and Naito S: Molecular targeting
therapy for renal cell carcinoma. Int J Clin Oncol. 11:209–213.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mulders P: Vascular endothelial growth
factor and mTOR pathways in renal cell carcinoma: differences and
synergies of two targeted mechanisms. BJU Int. 104:1585–1589. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshimoto T, Matsuura K, Karnan S, et al:
High-resolution analysis of DNA copy number alterations and gene
expression in renal clear cell carcinoma. J Pathol. 213:392–401.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peiffer DA, Le JM, Steemers FJ, et al:
High-resolution genomic profiling of chromosomal aberrations using
Infinium whole-genome genotyping. Genome Res. 16:1136–1148. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen M, Ye Y, Yang H, et al: Genome-wide
profiling of chromosomal alterations in renal cell carcinoma using
high-density single nucleotide polymorphism arrays. Int J Cancer.
125:2342–2348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yokomizo A, Mai M, Tindall DJ, et al:
Overexpression of the wild type p73 gene in human bladder cancer.
Oncogene. 18:1629–1633. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pfeifer D, Pantic M, Skatulla I, et al:
Genome-wide analysis of DNA copy number changes and LOH in CLL
using high-density SNP arrays. Blood. 109:1202–1210. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choueiri TK, Plantade A, Elson P, et al:
Efficacy of sunitinib and sorafenib in metastatic papillary and
chromophobe renal cell carcinoma. J Clin Oncol. 26:127–131. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Higgins JP: Gene array studies in renal
neoplasia. Scientific World Journal. 6:502–511. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thrash-Bingham CA, Salazar H, Freed JJ,
Greenberg RE and Tartof KD: Genomic alterations and instabilities
in renal cell carcinomas and their relationship to tumor pathology.
Cancer Res. 55:6189–6195. 1995.PubMed/NCBI
|
|
15
|
Klatte T, Pantuck AJ, Said JW, et al:
Cytogenetic and molecular tumor profiling for type 1 and type 2
papillary renal cell carcinoma. Clin Cancer Res. 15:1162–1169.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Speicher MR, Schoell B, du Manoir S, et
al: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in
chromophobe renal cell carcinomas revealed by comparative genomic
hybridization. Am J Pathol. 145:356–364. 1994.PubMed/NCBI
|
